Journal of Capital Medical University ›› 2009, Vol. 30 ›› Issue (3): 273-276.doi: 10.3785/j.issn.1006-7795.2009.03.003

Previous Articles     Next Articles

Expression of Splicing Factor SF2/ASF in Childhood Leukemia Cell

GAO Hui-fang1,2, ZHANG Han1,2, PEI Pei3, LIU Yi1,2, LI Zhi-gang1,2, JIANG Jin1,2, ZHANG Rui-dong1,2, GAO Chao1,2, QI Yu3, ZHENG Hu-yong1,2   

  1. 1. Hematology Center, Beijing Children's Hospital, Capital Medical University;2. Department of Oncology, Capital Medical University;3. Department of Pediatrics, First Hospital, Peking University
  • Received:2009-03-18 Revised:1900-01-01 Online:2009-06-21 Published:2009-06-21

Abstract:

Objective To investigate the expression of splicing factor SF2/ASF in pediatric acute B-lymphoblastic leukemia(B-ALL) cells and in leukemia cell lines treated with chemotherapeutic agents. Methods The protein levels of SF2/ASF were measured in bone marrow samples during preliminary diagnosis and complete remission(CR) B-ALL children by Western blotting; the protein levels of SF2/ASF, before and after vincristine and cytarabine treatment of B-ALL cell line of NALM-6, were also detected by Western blotting. Results Western blotting showed there was a strong SF2/ASF expression in children with preliminarily diagnosed B-ALL children compared with that in children who had complete remission and in children of the control group composed of idiopathic thrombocytopenic purpura(ITP) cases; high expression of SF2/ASF was detected in NALM-6 cell lines, but the expression reduced after treatment with cytarabine and vincristine. Conclusion Splicing factor SF2/ASF was expressed significantly higher in bone marrow of B-ALL children and leukemia cells, but was down-regulated in CR patients and in B-ALL cells treated with cytarabine and vincristine, indicating that SF2/ASF is a practical marker for monitoring outcome of B-ALL treatment.

Key words: leukemia, splicing factor, SF2/ASF, vincristine, cytarabine

CLC Number: